Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
Matching articles
Showing 1–12 of 77 articles · Interpret the evidence
- Interpret the evidence
Why the Duchenne trial ended early
ACE-031 is an investigational fusion protein that captures myostatin and related signaling proteins through a soluble piece of activin receptor type IIB. An older human study, first published online in 2016, asked how boys with Duchenne muscular dystrophy tolerated that approach.
ACE-0312 sources (2016, 2026)
- Interpret the evidence
Why bigger muscles did not settle the FSHD trial
ACE-083 is an investigational fusion protein based on follistatin. It was engineered to sequester myostatin, activins and other signals around a targeted muscle.
ACE-0831 source (2022)
- Interpret the evidence
What a rabbit knee study can tell us about AOD-9604
AOD-9604 is a modified peptide from the tail of human growth hormone. In an older animal experiment, researchers tested whether it changed measures of knee cartilage damage when studied alone or with hyaluronic acid. Hyaluronic acid is a large sugar-based molecule found in joint fluid.
AOD-96042 sources (2015, 2024)
- Interpret the evidence
How the diabetes trial separated symptoms from glucose markers
ARA-290 is an experimental 11-amino-acid peptide designed from erythropoietin to study tissue responses without reproducing its red-blood-cell stimulus.
ARA-2902 sources (2008, 2015)
- Interpret the evidence
What three dental nerve cases can tell us about a mixture
BPC-157 is a synthetic 15-amino-acid peptide. TB-500 can refer to a synthetic acetylated seven-amino-acid fragment of thymosin beta-4, although an experimental report needs to identify what its authors used.
BPC-157 / TB-5002 sources (2012, 2026)
- Interpret the evidence
What the four groups in a rat tendon study could compare
BPC-157 is a synthetic 15-amino-acid peptide. TB-500 commonly denotes an acetylated seven-amino-acid fragment of thymosin beta-4. In July 2026, investigators used BPC-157 and a reagent they called TB-500 to ask whether giving them together changed healing after Achilles tendon repair in rats.
BPC-157 / TB-5002 sources (2012, 2026)
- Interpret the evidence
Why collagen appearance and tendon strength can tell different stories
BPC-157 is a synthetic 15-amino-acid peptide. TB-500 generally refers to an acetylated seven-amino-acid fragment of thymosin beta-4. In a 2026 study of rat Achilles tendons, the investigators used BPC-157 and a supplier reagent labeled TB-500.
BPC-157 / TB-5002 sources (2012, 2026)
- Interpret the evidence
What an older knee chart review actually compared
BPC-157 is a synthetic 15-amino-acid peptide. TB-500 usually refers to an acetylated seven-amino-acid fragment of thymosin beta-4. An older 2021 knee report described BPC-157 together with a substance called TB4.
BPC-157 / TB-5002 sources (2012, 2021)
- Interpret the evidence
Why REIMAGINE 2 compared cagrilintide with semaglutide
Cagrilintide is an investigational long-acting peptide modeled on amylin. Semaglutide acts on the GLP-1 receptor. REIMAGINE 2 studied the two peptides alone and together in people with type 2 diabetes and overweight or obesity.
Cagrilintide2 sources (2025, 2026)
- Interpret the evidence
What a cagrilintide combination changed in a basal insulin trial
Cagrilintide is an investigational peptide designed to act like the hormone amylin for longer. In the 2026 REIMAGINE 3 study, researchers asked what changed when the cagrilintide–semaglutide combination, called CagriSema, was added to basal insulin in adults with type 2 diabetes.
Cagrilintide1 source (2026)
- Interpret the evidence
What the Japan and Taiwan CagriSema trial adds to the evidence
Cagrilintide is a long-acting investigational amylin-based peptide. CagriSema pairs it with the GLP-1 receptor agonist semaglutide. In REDEFINE 5, researchers examined whether the combination produced a different weight change from semaglutide alone in adults studied in Japan and Taiwan.
Cagrilintide1 source (2026)
- Interpret the evidence
What the growth hormone–releasing hormone receptor can tell us
CJC-1295 No DAC commonly refers to Mod GRF (1–29), a synthetic 29-residue relative of growth hormone–releasing hormone (GHRH) with four substitutions. Its design raises a specific question about how the original hormone engages its receptor.
CJC-1295 No DAC2 sources (2020, 2024)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
